231 related articles for article (PubMed ID: 33501870)
1. Bioadhesive polymer/lipid hybrid nanoparticles as oral delivery system of raloxifene with enhancive intestinal retention and bioavailability.
Du X; Gao N; Song X
Drug Deliv; 2021 Dec; 28(1):252-260. PubMed ID: 33501870
[TBL] [Abstract][Full Text] [Related]
2. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis.
Saini D; Fazil M; Ali MM; Baboota S; Ali J
Drug Deliv; 2015; 22(6):823-36. PubMed ID: 24725026
[TBL] [Abstract][Full Text] [Related]
3. In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance.
Ahmed OA; Badr-Eldin SM
Int J Nanomedicine; 2018; 13():6325-6335. PubMed ID: 30349253
[TBL] [Abstract][Full Text] [Related]
4. Raloxifene-loaded SLNs with enhanced biopharmaceutical potential: QbD-steered development, in vitro evaluation, in vivo pharmacokinetics, and IVIVC.
Jain A; Sharma T; Kumar R; Katare OP; Singh B
Drug Deliv Transl Res; 2022 May; 12(5):1136-1160. PubMed ID: 33966178
[TBL] [Abstract][Full Text] [Related]
5. Enhanced bioavailability of raloxifene hydrochloride via dry suspensions prepared from drug/HP-β-cyclodextrin inclusion complexes.
Lu R; Liu S; Wang Q; Li X
Pharmazie; 2015 Dec; 70(12):791-7. PubMed ID: 26817276
[TBL] [Abstract][Full Text] [Related]
6. Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal.
Elsheikh MA; Elnaggar YS; Gohar EY; Abdallah OY
Int J Nanomedicine; 2012; 7():3787-802. PubMed ID: 22888234
[TBL] [Abstract][Full Text] [Related]
7. Poly (ε-caprolactone) nanocapsules for oral delivery of raloxifene: process optimization by hybrid design approach, in vitro and in vivo evaluation.
Aditya N; Ravi PR; Avula US; Vats R
J Microencapsul; 2014; 31(5):508-18. PubMed ID: 24697167
[TBL] [Abstract][Full Text] [Related]
8. Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, in vivo evaluation and uptake mechanism.
Ravi PR; Aditya N; Kathuria H; Malekar S; Vats R
Eur J Pharm Biopharm; 2014 May; 87(1):114-24. PubMed ID: 24378615
[TBL] [Abstract][Full Text] [Related]
9. Self-Assembling Raloxifene Loaded Mixed Micelles: Formulation Optimization, In Vitro Cytotoxicity and In Vivo Pharmacokinetics.
Kanade R; Boche M; Pokharkar V
AAPS PharmSciTech; 2018 Apr; 19(3):1105-1115. PubMed ID: 29181706
[TBL] [Abstract][Full Text] [Related]
10. QbD-based optimization of raloxifene-loaded cubosomal formulation for transdemal delivery: ex vivo permeability and in vivo pharmacokinetic studies.
Gupta T; Kenjale P; Pokharkar V
Drug Deliv Transl Res; 2022 Dec; 12(12):2979-2992. PubMed ID: 35462597
[TBL] [Abstract][Full Text] [Related]
11. Oral Bioavailability Enhancement of Raloxifene with Nanostructured Lipid Carriers.
Murthy A; Ravi PR; Kathuria H; Malekar S
Nanomaterials (Basel); 2020 May; 10(6):. PubMed ID: 32486508
[TBL] [Abstract][Full Text] [Related]
12. Vitamin E TPGS based transferosomes augmented TAT as a promising delivery system for improved transdermal delivery of raloxifene.
Alhakamy NA; Fahmy UA; Ahmed OAA
PLoS One; 2019; 14(12):e0226639. PubMed ID: 31881053
[TBL] [Abstract][Full Text] [Related]
13. Transdermal delivery of raloxifene HCl via ethosomal system: Formulation, advanced characterizations and pharmacokinetic evaluation.
Mahmood S; Mandal UK; Chatterjee B
Int J Pharm; 2018 May; 542(1-2):36-46. PubMed ID: 29501737
[TBL] [Abstract][Full Text] [Related]
14. Oral bioavailability enhancement of raloxifene by developing microemulsion using D-optimal mixture design: optimization and in-vivo pharmacokinetic study.
Shah N; Seth A; Balaraman R; Sailor G; Javia A; Gohil D
Drug Dev Ind Pharm; 2018 Apr; 44(4):687-696. PubMed ID: 29168671
[TBL] [Abstract][Full Text] [Related]
15. Raloxifene encapsulated spanlastic nanogel for the prevention of bone fracture risk via transdermal administration: Pharmacokinetic and efficacy study in animal model.
Ansari MD; Shafi S; Pandit J; Waheed A; Jahan RN; Khan I; Vohora D; Jain S; Aqil M; Sultana Y
Drug Deliv Transl Res; 2024 Jun; 14(6):1635-1647. PubMed ID: 37996726
[TBL] [Abstract][Full Text] [Related]
16. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability.
Kushwaha AK; Vuddanda PR; Karunanidhi P; Singh SK; Singh S
Biomed Res Int; 2013; 2013():584549. PubMed ID: 24228255
[TBL] [Abstract][Full Text] [Related]
17. QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: extensive in vitro and in vivo evaluation studies.
Pant A; Sharma G; Saini S; Kaur G; Jain A; Thakur A; Singh B
Drug Deliv Transl Res; 2024 Mar; 14(3):730-756. PubMed ID: 37768530
[TBL] [Abstract][Full Text] [Related]
18. Glucose-Based Mesoporous Carbon Nanospheres as Functional Carriers for Oral Delivery of Amphiphobic Raloxifene: Insights into the Bioavailability Enhancement and Lymphatic Transport.
Ye Y; Zhang T; Li W; Sun H; Lu D; Wu B; Zhang X
Pharm Res; 2016 Mar; 33(3):792-803. PubMed ID: 26553355
[TBL] [Abstract][Full Text] [Related]
19. Physically Optimized Nano-Lipid Carriers Augment Raloxifene and Vitamin D Oral Bioavailability in Healthy Humans for Management of Osteoporosis.
Hosny KM; Bahmdan RH; Alhakamy NA; Alfaleh MA; Ahmed OA; Elkomy MH
J Pharm Sci; 2020 Jul; 109(7):2145-2155. PubMed ID: 32194094
[TBL] [Abstract][Full Text] [Related]
20. A matrix dispersion based on phospholipid complex system: preparation, lymphatic transport, and pharmacokinetics.
Li H; Lu S; Luo M; Li X; Liu S; Zhang T
Drug Dev Ind Pharm; 2020 Apr; 46(4):557-565. PubMed ID: 32126844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
